Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318930 | 0.84 | GPR119 (0.48) | MEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL25120232 | 0.84 | GPR119 (0.48) | MEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL12420773 | 0.83 | PROKR1 (0.43) | ALDH1A1HPGDPROKR1SCN9A | |
| Hydrochloric Acid SCHEMBL2195999 | 0.82 | PROKR1 (0.42) | ALDH1A1HPGDPROKR1SCN9A | |
| SCHEMBL2198288 | 0.82 | SCN9A (0.52) | MEN1KMT2AABL1RIN1GPR119 | |
| SCHEMBL12509165 | 0.80 | ALDH1A1 (0.41) | MEN1KMT2AFAAHALDH1A1HPGD | |
| SCHEMBL25120372 | 0.79 | NAMPT (0.48) | FAAHALDH1A1GAA | |
| SCHEMBL12508542 | 0.78 | FAAH (0.43) | FAAHALDH1A1 | |
| SCHEMBL12509388 | 0.78 | ALDH1A1 (0.42) | KMT2AFAAHALDH1A1PROKR1 | |
| SCHEMBL12509168 | 0.78 | FAAH (0.43) | MEN1KMT2AFAAHALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | MEN1 4707/4885KMT2A 1156/4885ABL1 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.